CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
12 Gennaio 2024 - 2:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
Sean McCarthy, D.Phil., president, chief executive officer, and
chairman, will participate in a fireside chat at the B. Riley
Securities Virtual Annual Oncology Investor Conference on Thursday,
January 18, 2024 at 1:00 p.m. ET.
To access this event, please reach out to your B. Riley
Securities sale representative for a recording of the fireside
chat.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics designed to
be localized to the tumor microenvironment. By pioneering a novel
pipeline of localized biologics, powered by its Probody®
therapeutic platform, CytomX’s vision is to create safer, more
effective therapies for the treatment of cancer. CytomX’s robust
and differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engagers, and immune modulators such as cytokines
and checkpoint inhibitors. CytomX’s clinical pipeline includes the
cancer immunotherapeutic candidates CX-904 and BMS-986288. CX-904,
partnered with Amgen, is a conditionally activated T-cell-engaging
antibody targeting the epidermal growth factor receptor (EGFR) on
tumor cells and the CD3 receptor on T cells. BMS-986288, partnered
with Bristol Myers Squibb, is a conditionally activated
CTLA-4-targeting antibody that is a non-fucosylated version of
ipilimumab. In addition, CytomX has a diverse, emerging portfolio
of wholly-owned drug candidates including CX-2051, a conditionally
activated ADC directed toward epithelial cell adhesion molecule,
EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers, and CX-801, an interferon
alpha-2b Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors. CytomX has established strategic collaborations with
multiple leaders in oncology, including Amgen, Astellas, Bristol
Myers Squibb, Regeneron and Moderna. For more information about
CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Investor Contact:Chris
OgdenSVP, Finance and Accounting cogden@cytomx.com(317)
767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
Grafico Azioni CytomX Therapeutics (NASDAQ:CTMX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni CytomX Therapeutics (NASDAQ:CTMX)
Storico
Da Set 2023 a Set 2024